NCT05332730View on ClinicalTrials.gov

A Study on Pharmacokinetics and Safety of BAT2506 Injection Versus Simponi®

PHASE1CompletedINTERVENTIONAL
Enrollment

375

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

June 27, 2023

Study Completion Date

July 10, 2023

Conditions
Psoriatic Arthritis
Interventions
DRUG

BAT2506 injection

50 mg, subcutaneous administration

DRUG

Simponi® (EU commercially available product)

50 mg, subcutaneous administration

DRUG

Simponi® (US commercially available product)

50 mg, subcutaneous administration

Trial Locations (1)

Unknown

The First Bethune Hospital of Jilin University, Changchun

Sponsors
All Listed Sponsors
collaborator

The First Hospital of Jilin University

OTHER

lead

Bio-Thera Solutions

INDUSTRY